Summary of findings for the main comparison. Perazine versus placebo for schizophrenia.
| Perazine versus placebo for schizophrenia | ||||||
| Patient or population: patients with schizophrenia Settings: hospital Intervention: perazine versus placebo | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Control | Perazine versus placebo | |||||
| Acceptability of treatment Leaving the study early due to any reason Follow‐up: mean 5 weeks | 422 per 1000 | 262 per 1000 (148 to 464) | RR 0.62 (0.35 to 1.1) | 95 (1 study) | ⊕⊝⊝⊝ very low1,2,3 | |
| Global state change over time (no better or deterioration) Follow‐up: mean 5 weeks | 467 per 1000 | 201 per 1000 (107 to 378) | RR 0.43 (0.23 to 0.81) | 95 (1 study) | ⊕⊕⊝⊝ low1,3 | |
| Overall mental state less than 30% BPRS reduction Follow‐up: mean 5 weeks | 733 per 1000 | 601 per 1000 (447 to 799) | RR 0.82 (0.61 to 1.09) | 95 (1 study) | ⊕⊕⊝⊝ low1,3 | |
| Movement disorders number of participants receiving antiparkinson medication Follow‐up: mean 5 weeks | 44 per 1000 | 200 per 1000 (46 to 864) | RR 4.5 (1.04 to 19.45) | 95 (1 study) | ⊕⊝⊝⊝ very low1,3,4 | |
| Overall tolerability Leaving the studies early due to adverse events | See comment | See comment | Not estimable | 0 (0) | See comment | No data available |
| Satisfaction with care ‐ not reported | See comment | See comment | Not estimable | ‐ | See comment | No data available |
| Quality of life ‐ not reported | See comment | See comment | Not estimable | ‐ | See comment | No data available |
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Risk of bias: high risk of attrition bias. 2 Indirectness: acceptability was measured by the number of participants leaving the studies for any reason which is an indirect measure of acceptability. 3 Imprecision: very small number of events. 4 Indirectness: movement disorders were measured by the number of participants receiving antiparkinson medication which is an indirect measure of adverse events.